Alemtuzumab: autoimmune complications

Evidence-based neurology checklist on alemtuzumab: autoimmune complications: Thyroid Hypothyroidism Hyperthyroidism Grave’s orbitopathy Renal Haematological Dermatological Other autoimmune side effects Acronym: ITP

Thyroid

  • Hypothyroidism
  • Hyperthyroidism
  • Grave’s orbitopathy

Renal

Haematological

Dermatological

Other autoimmune side effects

Acronym: ITP

References

  1. Dargahi N, Katsara M, Tselios T, et al. Multiple sclerosis: immunopathology and treatment update. Brain Sci 2017; 7(7) pii: E78.
  2. Havrdova E, Arnold DL, Cohen JA, et al; CARE-MS I and CAMMS03409 Investigators. Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy. Neurology 2017; 89:1107-1116.
  3. Roos JCP, Moran C, Chatterjee VK, Jones J, Coles A, Murthy R. Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves' orbitopathy: a case series. Eye (Lond) 2019; 33:223-229.
  4. Phelps R, Winston JA, Wynn D, et al. Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. Mult Scler 2019; doi: 10.1177/1352458519841829 (Epub ahead of print).
  5. Cuker A, Bass AD, Nadj C, et al. Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management. Mult Scler 2019; 20:1352458518816612 (Epub ahead of print).
  6. And 18 more. Subscribe to see the full list

Related checklists

Loading...